Weight & appetite
Cagrilintide vs Retatrutide
Mechanisms differ (amylin analogue vs triple incretin/glucagon agonism); evidence strength and development stage must be compared, not declared a winner.
At a glance
Cagrilintide
Retatrutide
Human evidence
Cagrilintide has randomized Phase II weight-loss evidence and a Phase IIIa monotherapy arm within REDEFINE 1; cagrilintide 2.4 mg weekly produced roughly 11.5%-11.8% mean weight reduction at 68 weeks depending on estimand.
Randomized Phase II obesity data show major weight reduction. A 98-participant MASLD substudy also showed large dose-dependent liver-fat reductions, including >80% mean relative reduction at the two highest studied doses by week 24.
Research focus
Obesity, appetite and weight-management research
Obesity, weight management, metabolic disease
Regulatory status
FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law.
Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding.
Route / formulation
Trial evidence does not establish quality or equivalence of research-market material.
Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens.
No direct head-to-head outcome trial identified Mechanisms differ (amylin analogue vs triple incretin/glucagon agonism); evidence strength and development stage must be compared, not declared a winner.